Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. Izervay was approved by the FDA just over a year ago, shortly after Astellas ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic atrophy (GA) med Izervay has taken a few beatings in recent months. Still, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results